Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/25/2025 | $31.00 | Buy | Guggenheim |
| 9/20/2024 | $2.00 → $35.00 | Hold → Buy | Jefferies |
| 9/13/2021 | $3.50 | Neutral | HC Wainwright & Co. |
| 9/2/2021 | Outperform → Market Perform | William Blair |
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort – – Mean plasma HBV DNA reductions of 3.2 logs IU/mL over 28 days of treatment for 400 mg cohort consistent with findings in 150 mg cohort, supporting ability of 150 mg dose to achieve saturated inhibition of viral replication, as anticipated – – Trial completion triggers opt-in point under collaboration with Gilead Sciences, Inc. following delivery and review of option data package – SOUTH SAN FRANCISCO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovativ
SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that Jason Okazaki, chief executive officer and president, and Anuj Gaggar, MD, PhD, chief medical officer, will present in a fireside chat during the Jefferies 2025 Global Healthcare Conference at 8:45 a.m. Eastern Time on June 4, 2025. A live webcast will be available on the Events and Presentations section of Assembly Bio's website and a replay will be accessible following the event. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/eve
– Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 – – New data from multiple programs highlighted at ICAR, ESCMID and EASL 2025 – SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent updates for the first quarter ended March 31, 2025. "We continue the strong progress across our antiviral portfolio and remain on track for the multiple key clin
Guggenheim initiated coverage of Assembly Biosciences with a rating of Buy and set a new price target of $31.00
Jefferies upgraded Assembly Biosciences from Hold to Buy and set a new price target of $35.00 from $2.00 previously
HC Wainwright & Co. initiated coverage of Assembly Biosciences with a rating of Neutral and set a new price target of $3.50
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)